Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 4, 2026Clinical EpigeneticsOpen Access

Azacitidine and decitabine show distinct response patterns in pediatric Myelodysplastic Syndromes and Juvenile Myelomonocytic Leukemia before HSCT: a systematic review and quantitative analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAlessandra CianfloneFCFrancesco CecereLCLuigi Coppola

Discussion

Loading...

Member takes

Overview

Systematic review evaluates pre-HSCT therapies in pediatric myeloid malignancies, indicating tailored treatment strategies are crucial.

Key Points

  • To evaluate the efficacy of pre-HSCT epigenetic therapy in pediatric hematologic malignancies like MDS and JMML.
  • Performed a systematic review and pooled analysis of seven studies involving 87 pediatric patients.
  • Analyzed treatment responses to azacitidine and decitabine prior to HSCT for MDS and JMML patients.
  • Utilized chi-squared, Fisher’s exact tests, and non-parametric tests for statistical analysis.
  • In MDS, complete remission achieved in 64.7% with DAC, leading to improved post-HSCT survival (84.2% vs. 42.8%).
  • In JMML, 47.2% had partial remission, while complete remission was rare at 11.1%.
  • Superior responses were noted in MDS compared to JMML, with strong associations to PTPN11 mutations.

Cite This Study

Cianflone et al. (2026) studied this question.

synapsesocial.com/papers/6a48a36b89561a0c2d78d5a1https://doi.org/10.1186/s13148-026-02191-0
View Full Paper
Ask AI
Bookmark
Share